Glen Burnie, MDNCT06764615Now EnrollingIRB Ready

Crohn's Disease Clinical Trial in Glen Burnie, MD

Access cutting-edge crohn's disease treatment through this phase 2 clinical trial at a research site in Glen Burnie. Study-provided care at no cost to qualified participants.

Sponsored by Takeda

Quick Self-Assessment

See if you qualify for this Glen Burnie location

Preparing your pre-screening questions…

Expert Care in Glen Burnie

Access crohn's disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related crohn's disease treatment provided free

Apply for This Glen Burnie Location

Check if you qualify for this crohn's disease clinical trial in Glen Burnie, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Glen Burnie

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Glen Burnie site if eligible
  4. 4Begin participation

About This Crohn's Disease Study in Glen Burnie

Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461), TAK-279-UC-2001 (NCT06254950) and TAK-279-CD-2003 (NCT07403968). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able to continue to benefit from the treatment in this study. The main aim of this study is to find out how safe TAK-279 is for long term use and to check if it reduces bowel inflammation and symptoms when used for a longer period of time in adults with moderately to severely active UC or CD. The participants will be treated with TAK-279 for up to 3 years (156 weeks). During the study, participants will visit their study clinic around 15 times.

Sponsor: Takeda

Who Can Participate

Inclusion Criteria

The participant is willing and able to understand and fully comply with trial procedures and requirements (including digital tools and applications), in the opinion of the investigator. The participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent form \[ICF\]) and any required privacy authorization prior to the initiation of any trial procedures.
Completion of Week 52 in the parent trials (phase 2b CD and phase 2 UC) with valid electronic (e) Diary data for Week 52 (TAK-279-CD-2001 and TAK-279-UC-2001).
Clinical or symptomatic responder at parent trial Week 52 as defined below:
TAK-279-CD-2001: Clinical response at Week 52 of the parent trial based on PRO2, assessed as \>=30% decrease in average daily very soft or liquid stools and/ or \>=30% decrease in average AP from parent trial baseline.
TAK-279-UC-2001: Symptomatic response at Week 52 of the parent trial, assessed as a reduction in partial modified Mayo score (pmMS) of \>=1 points and \>=30% from parent trial baseline; and a decrease from parent trial baseline in the rectal bleeding sub-score of \>=1 point or an absolute rectal bleeding sub-score of \<=1 point.
TAK-279-CD-2003: Endoscopic response at Week 12 of the parent trial, assessed as a participant achieving decrease in SES-CD \>50% from baseline (or for participants with isolated ileal disease, SES-CD \<=4 or at least a 2-point reduction from baseline). Other General Inclusion Criteria:
Participants must meet the contraception recommendations.

Exclusion Criteria

Participant considered by the investigator to be unsuitable for the OLE trial due to their trial compliance and medication adherence concerns.
Participants with malignancy or dysplasia per endoscopy any time during the parent trial or at the beginning of the OLE. Exclusion Criteria related to Laboratory Investigations:
Participants meeting the exclusion criteria related to laboratory investigations as defined in the protocol. Exclusion criteria related to other prohibited concomitant medication for TAK-279-CD-2001 and TAK-279-UC-2001 Cohorts:
Participants taking oral corticosteroids for CD or UC during parent trial at or after Week 48.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Glen Burnie?

Yes, this clinical trial (NCT06764615) has an active research site in Glen Burnie, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Crohn's Disease Treatment Options in Glen Burnie, MD

If you're searching for crohn's disease treatment options in Glen Burnie, MD, this clinical trial (NCT06764615) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Glen Burnie research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced crohn's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all crohn's disease clinical trials near you to find additional studies recruiting in your area.

More Crohns Disease Trials in Glen Burnie, MD

See all crohns disease clinical trials recruiting in Glen Burnie — not just this study.

Browse Crohns Disease Trials in Glen Burnie →

Browse More Trials by Condition

Crohns Disease TrialsAnkylosing Spondylitis TrialsInflammatory Bowel Disease TrialsAll Conditions →

Ready to Join in Glen Burnie?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Glen Burnie, MD